Shattuck Labs, Inc. develops monoclonal and bispecific DR3-blocking antibodies for inflammatory and immune-mediated diseases. The company’s news centers on SL-325, a Death Receptor 3 antibody targeting the DR3/TL1A pathway, with emphasis on clinical development in inflammatory bowel disease and related immune-mediated conditions.
Recurring updates also cover quarterly financial results, cash and capital-structure disclosures, investor conference participation, inducement equity awards, and governance matters tied to Shattuck’s Nasdaq-listed common stock.
Shattuck Labs (STTK) announced two upcoming poster presentations at United European Gastroenterology Week 2026, taking place October 17–20 in Barcelona, Spain.
A moderated poster on the development and characterization of SL-846 is scheduled for October 19. An ePoster on TL1A immune complexes and anti-drug antibodies will be available throughout the congress. Both posters will be posted on the company’s website following the congress.
Shattuck Labs (NASDAQ: STTK) plans to evaluate SL-325 in a Phase 2 trial for patients with moderate to severe hidradenitis suppurativa (HS). HS becomes SL-325's second Phase 2 indication, expanding development beyond inflammatory bowel disease. The company expects the RECEPTIVE-HS1 trial to begin in 2026, with an investigational new drug application submission in October 2026 and Week 16 results in the first half of 2028.
The randomized, double-blind trial will compare two SL-325 doses with placebo, with expected enrollment of approximately 150 patients. A 16-week placebo-controlled treatment period will precede an SL-325 extension through Week 52. The primary endpoint measures patients achieving at least a 50% reduction in abscesses and inflammatory nodules without increased abscess or draining tunnel counts. Shoba Ravichandran joins as clinical development head to lead the HS program. Shattuck still expects existing cash to fund operations into 2029.
Shattuck Labs (STTK) will participate in two September healthcare investor conferences via fireside chats and one-on-one meetings.
Management, including CEO Taylor Schreiber and CFO Andrew Neill, will present at the Wells Fargo 21st Annual Healthcare Conference on September 8, 2026 at 11:00 AM ET and at the Cantor Global Healthcare Conference on September 9, 2026 at 3:55 PM ET. Live and replay webcasts will be available through the company’s investor relations website.
Shattuck Labs (NASDAQ: STTK) reported second quarter 2026 results and pipeline progress, highlighted by Phase 1 data for lead DR3 blocker SL-325 showing a favorable safety profile, 3.7% antidrug antibody incidence, durable TL1A/DR3 blockade for over three months at ≥1 mg/kg, and no DR3 agonism.
The RECEPTIVE-CD1 randomized, double-blind, placebo-controlled Phase 2b trial in ~232 Crohn’s disease patients is expected to start in Q3 2026, with 12-week endoscopic response data in H1 2028. Bispecific DR3 x IL-23R candidate SL-846 is in GLP toxicology, with a Phase 1 trial and initial data planned for 2027. Cash, cash equivalents and short-term investments rose to $208.3 million at June 30, 2026, helped by an $86.2 million public offering and $57.1 million warrant exercises, and are expected to fund operations into 2029. Q2 2026 net loss was $15.2 million with no revenue.
Shattuck Labs (NASDAQ: STTK) priced a public offering of 10,879,376 common shares at $4.00 and pre-funded warrants for up to 7,870,624 shares at $3.9999 each. Gross proceeds are expected to be about $75 million before expenses. Closing is expected on June 11, 2026, with underwriters holding a 30-day option to buy up to 2,812,500 additional shares.
Shattuck Labs (NASDAQ: STTK) commenced a proposed public offering of common stock and, for certain investors, pre-funded warrants to purchase common shares. All securities will be offered by Shattuck.
Underwriters are expected to receive a 30-day option to buy up to an additional 15% of shares. The offering’s completion, size and terms remain subject to market and other conditions under an effective SEC registration.
Shattuck Labs (NASDAQ: STTK) reported that holders have exercised or given notices to exercise approximately 50.6 million common stock warrants, about 96% of warrants issued in the August 4, 2025 private placement. This is expected to generate roughly $54.9 million in gross proceeds, including $5.6 million received by March 31, 2026 and an additional $49.3 million anticipated. Combined with $90.4 million in cash, cash equivalents and short-term investments as of March 31, 2026, Shattuck expects to fund operations into 2029, based on current plans.
Shattuck Labs (NASDAQ: STTK) reported Phase 1 results for DR3-blocking antibody SL-325 in 72 healthy volunteers. Only 3.7% (2/54) developed low‑titer antidrug antibodies, with no impact on PK or receptor occupancy. Complete DR3 occupancy occurred at ≥0.1 mg/kg, with TL1A blockade lasting over 10 weeks.
SL-325 showed no DR3 agonism, no cytokine changes, and only Grade 1 treatment-related adverse events, with no serious events. A Phase 2b Crohn’s disease trial is expected to start in Q3 2026, and bispecific candidate SL-846 is progressing through IND-enabling toxicology.
Shattuck Labs (NASDAQ: STTK) will host an investor call and webcast on June 8, 2026 at 8:00 a.m. ET to present comprehensive Phase 1 clinical data for SL-325, a potentially first-in-class DR3 blocking antibody, and provide a pipeline update.
The event will feature Shattuck’s management team and include a Q&A session, with live and replay access via the company’s website.
Shattuck Labs (NASDAQ: STTK) reported Q1 2026 results and program milestones on May 7, 2026. Cash and short-term investments were $90.4M as of March 31, 2026, up from $60.9M a year earlier. Q1 net loss was $14.8M (or $0.13 per share). Enrollment in the Phase 1 trial of SL-325 is complete; full Phase 1 data are expected in Q2 2026 and a Phase 2 trial in Crohn’s disease is planned for Q3 2026. The lead bispecific antibody has entered IND-enabling activities. Cash runway is expected into 2029 assuming full exercise of outstanding warrants.